View here all publications related to the biomarker CAF.
View here all publications related to the biomarker CAF. Below 3 recent publications for the use of CAF:
Early postoperative C-terminal agrin fragment (CAF) serum levels predict graft loss and proteinuria in renal transplant recipients. Steubl D, Vogel A, Hettwer S, Tholen S, Luppa PB, Rondak IC, Renders L, Heemann U, Roos M. Clin Chem Lab Med. 2015 Jun 18.
Sarcopenia - The search for emerging biomarkers. Kalinkovich A, Livshits G. Ageing Res Rev. 2015 Jul;22:58-71.
C-terminal agrin fragment (CAF) reflects renal function in patients suffering from severe sepsis or septic shock. Drey M, Behnes M, Kob R, Lepiorz D, Hettwer S, Bollheimer C, Sieber CC, Bertsch T, Hoffmann U. Clin Lab. 2015;61(1-2):69-76.
View here all publications related to the biomarker CAF. Below 2 recent publications for the use of CAF as renal functional marker.
C-terminal agrin fragment (CAF) as a serum biomarker for residual renal function in peritoneal dialysis patients. Steubl D, Hettwer S, Dahinden P, Luppa P, Rondak IC, Regenbogen C, Stock KF, Renders L, Heemann U, Roos M. Int Urol Nephrol. 2014 Oct 29.
C-Terminal Agrin Fragment (CAF) Reflects Renal Function in Patients Suffering from Severe Sepsis or Septic Shock. M
View here all publications related to the biomarker CAF. Below the 3 most recent publications are listed:
Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients. Marzetti E, Calvani R, Lorenzi M, Marini F, D'Angelo E, Martone AM, Celi M, Tosato M, Bernabei R, Landi F.
Exp Gerontol. 2014 Oct 7. pii: S0531-5565(14)00278-2. doi: 10.1016/j.exger.2014.10.003.
C-terminal agrin fragment is inversely related to neuromuscular fatigue in older men. Stout JR, Fragala MS, Hoffman JR, Iv EH, McCormack WB, Townsend JR, Jatjner AR, Emerson NS, Oliveira LP, Fukuda DH. Muscle Nerve. 2014 Sep 3. doi: 10.1002/mus.24443.
Influence of high-flux hemodialysis and hemodiafiltration on serum C-terminal agrin fragment levels in end-stage renal disease patients. Steubl D, Hettwer S, Dahinden P, Wolf P, Luppa P, Wagner CA, Küchle C, Schmaderer C, Renders L, Heemann U, Roos M. Transl Res. 2014 May 16. pii: S1931-5244(14)00168-6. doi: 10.1016/j.trsl.2014.05.005.
Neurotune has recently published 3 new scientific publications:
of a Soluble Fragment of Neural Agrin (NT-1654) Considerably Improves
the Muscle Pathology Caused by the Disassembly of the Neuromuscular
Junction.Hettwer S, Lin S, Kucsera S, Haubitz M, Oliveri F, Fariello RG, Ruegg MA, Vrijbloed JW. PLoS One. 2014 Feb 10;9(2):e88739. doi: 10.1371/journal.pone.0088739. eCollection 2014.
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Fariello RG, Ghelardini C, Di Cesare Mannelli L, Bonanno G, Pittaluga A, Milanese M, Misiano P, Farina C. Neuropharmacology. 2014 Jan 31. pii: S0028-3908(14)00036-7. doi: 10.1016/j.neuropharm.2014.01.029.
C-terminal agrin fragment - a new fast biomarker for kidney function in renal transplant recipients. Steubl D, Hettwer S, Vrijbloed W, Dahinden P, Wolf P, Luppa P, Wagner CA, Renders L, Heemann U, Roos M. Am J Nephrol. 2013;38(6):501-8. doi: 10.1159/000356969. Epub 2013 Dec 14.
The NTtotalCAF ELISA is now officially available.
Since its successful launch the NTCAF ELISA assay has been further developed.
The range of Neurotune's diagnostic assay to stratify sarcopenia patients is now extended to further body fluids beyond serum. Plasma and urine may also be used for the in vitro assessment of the sarcopenia biomarker CAF (C-terminal Agrin Fragment). For more information see the revised factsheet.
The ALS Therapy Development Institute Partners with Neurotune to investigate Potential Treatments for Motor Neuron Desease. Partnership aimed at Neuromuscular Junction Strength against Disease Course.
The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig's desease).
Experimental Gerontology - Elevated levels of a C-Terminal agrin fragment identifies a new subset of sarcopenia patients.
Neurotune launches the world's first ELISA based diagnostic assay for C-terminal Agrin Fragments (CAF) in blood.
Neurotune AG, a Swiss biopharmaceutical company, announces the launch of its immunoassay, NTCAF ELISA, the world's first ELISA based assay for sarcopenia.
BIOMARKERS AND IMAGING (International Conference on Sarcopenia Research). Report on the Journal of Nutrition, Health & Aging © (Volume 15, Number 10, 2011).
Neurotune AG is Coordinator of an Eurostars funded Project entitled “Early Diagnosis and Monitoring of Renal Diseases” (Acronym: KIDNEY).
The scope of the project is the validation of a new and most effective diagnostic biomarker (RCAF) for the early monitoring of chronic kidney disease with a possible application in the prognosis of kidney transplant and in acute kidney injury.
Neurotune AG has presented three scientific communications at the International Neuroscience Meeting held in Washington DC on Nov 12 -16, 2011. The data presented were reporting results of original experiments performed in Neurotune’s laboratories in Schlieren and others carried out in conjunction with researchers of University of Florence.
Schlieren (Zurich), Switzerland, 14 November 2011. The FDA has granted Neurotune AG an IND for dimiracetam, the company’s lead compound for treatment of neuropathic pain conditions. Neurotune is planning a pivotal study to demonstrate efficacy of dimiracetam in alleviating neuropathic pain in AIDS patients affected with a treatment related symmetrical painful peripheral neuropathy.
Erste Publikation des Amts für Wirtschaft und Arbeit - Interview mit Bruno Oesch
Bruno Oesch, Mitgründer der Prionics AG und Verwaltungsratspräsident der Neurotune AG, über die Wahrnehmung unseres Standortes und Synergien in der Life-Science-Branche.
Neurotune Strengthens Management
Neurotune AG, a Swiss biopharmaceutical company, today announced personnel changes in its board of directors as well as management.
Neurotune receives EU funding for sarcopenia project
Neurotune AG today announced it is leading a consortium of research teams in the DISARCO project, a two-year project focused on developing an immunoassay for the diagnosis of sarcopenia. The consortium has received €720,000 from the European Eurostars Programme to fund the research.
Der BIO-TECHNOPARK® Schlieren-Zürich ist zusammen mit Neurotune, ETH Zürich, Universität Zürich und der Standortförderung des Kantons Zürich Partner im EU-Projekt HealthTIES.
Neurotune announces positive top-line Phase IIa results for dimiracetam to treat neuropathic pain in HIV patients
Neurotune AG, a Swiss biopharmaceutical company, today announced positive top-line results from its phase IIa, safety and tolerability, study of dimiracetam (NT-11624), its lead compound for treatment-induced neuropathic pain in HIV patients receiving anti-retroviral medication.
Painless future: new members for Board of Directors, funding and clinical results outlook
The shareholders of Neurotune AG have elected Dr. Anders Härfstrand and Heinrich Rotach as new members of the board of directors at their annual general assembly on April 21, 2010.
Neurotune announces regulatory approval for Phase II Clinical Trial to treat neuropathic pain in HIV patients
Neurotune AG has received MCC ’s (the South African National Regulatory Agency) approval for a Phase II clinical study of Neurotune’s lead compound NT-11624 for neuropathic pain caused by treatment with anti-retroviral medication.
Change in the Management of Neurotune AG
Neurotune AG announces a change in the management. Starting March 1st 2009, Dr. Bruno Oesch will take over the position of Chief Executive Officer.
Neurotune successfully completes Phase I Trials with its Lead Compund NT-11624
Neurotune AG, a Swiss biopharmaceutical company, which has recently acquired two programs in neuropathic pain, announces the successful completion of Phase I for its lead compound NT-11624 developed for treatment of neuropathic and osteoarthritic pain. NT-11624, dimiracetam, is a selective small molecular NMDA-receptor antagonist, which acts on a new site of the receptor.
Neurotune expands its portfolio by acquiring neuropathic pain projects
Neurotune AG announces that the shareholders meeting, held on August 29th 2008, approved of the expansion of its portfolio with two programs in neuropathic pain. The company has reached an agreement with the Italy-based company Brane Discovery Srl. to acquire rights for two programs in neuropathic pain in a combined cash and share transaction.
Neurotune completes next funding round
Neurotune AG announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostical methods. Part of the capital will be used to extend a developmental pipeline.
Neurotune moves to new laboratories and starts the preclinical development of initial candidate substances for the treatment of sarcopenia
Neurotune AG has moved to new laboratory and office facilities at the Biotech Centre in Zurich on 1st November 2007.
Neurotune expands its management by taking on an expert for preclinical development and appointing a new CFO
Neurotune AG has taken on Dr. Jan Willem Vrijbloed for the expansion of its preclinical development division, and has appointed Michael Kregar as the new Chief Financial Officer (CFO).
Neurotune AG is honoured on the occasion of the award ceremony „ZKB Pioneer Award TECHNOPARK® 2007“
Neurotune AG was awarded a prize for its activity in the area of developing drugs to treat age-related muscle atrophy – Sarcopenia – and other disorders of the human nervous system on Tuesday evening.
Neurotune to present during the Next Wave Session at the BioEquity 2007, in Glasgow, Scotland.
For more information, please see http://www.ebdgroup.com/bioequity/
Neurotune announces closing of 3rd Seed Financing Round
With the conclusion of its third Seed Round Financing, Neurotune adds another CHF 3.3 Mio to its funds.
Neurotune AG and NiKem Research Srl enter into a Research Service Agreement
Neurotune and NiKem Research announced that the two companies have signed a 12 months Research Service Agreement on 1 February, 2007.
Neurotune to present at the BioEurope 2006, November 6-8, Düsseldorf, Germany.
For more information, please see www.ebdgroup.com/bioeurope/
Neurotune to present at the 2nd Swiss-Scandinavian Bio-Business Seminar, October 13, 2006, Zürich, Switzerland.
For more information, please see www.greaterzuricharea.ch
Meet us at the Biobusiness Network 2006 Partnering Conference at the Hotel President Wilson, Geneva, Switzerland.
For more information, please see www.biobusiness-partnering.com
Neurotune announces second closing of Seed Financing Round
With the conclusion of its Second Seed Round Financing Neurotune adds another CHF 2.5 Mio to its funds.
Press Release N°: 2006/03
Neurotune successfully concludes CHF 4.9 Mio. Private Equity Financing Round
Second Seed Round Financing through Private Equity and Loan from Existing and New Investors.
Press Release N°: 2006/02
Neurotune appoints new CEO Dr. Andreas J. Schulze is new CEO of Neurotune AG.
Press Release N°: 2006/01